RE:PD-(L)1 checkpoint inhibitors to reach $58 Billion by 2025MISSISSAUGA, ON, April 23, 2024 /CNW/ - Roche Canada is pleased to announce that on March 13, 2024, Health Canada issued marketing authorization for Tecentriq® SC (atezolizumab, solution for subcutaneous injection), the first cancer immunotherapy for subcutaneous (under the skin injection) administration in Canada, for specific indications in lung cancer, hepatocellular carcinoma (HCC or liver cancer), and breast cancer.
https://www.biospace.com/article/releases/health-canada-authorizes-tecentriq-and-174-sc-atezolizumab-solution-for-subcutaneous-injection-the-first-cancer-immunotherapy-subcutaneous-injection-for-multiple-cancer-types/